11:12 AM EST, 11/07/2024 (MT Newswires) -- Nektar Therapeutics ( NKTR ) said Thursday that its experimental cancer treatment, NKTR-255, combined with durvalumab, sped up the recovery of immune cells in patients who had completed radiation therapy.

The interim analysis of the phase 2 study showed that NKTR-255 reversed radiation-induced lymphopenia in patients with locally advanced non-small cell lung cancer, according to the company.

Nektar said NKTR-255, when combined with durvalumab after radiation therapy, significantly improved the recovery of lymphocytes after 8 weeks compared to patients who received radiation therapy alone or radiation therapy with durvalumab.

Shares of the company were down 2.1% in recent trading.

Price: 1.37, Change: -0.02, Percent Change: -1.44